We are live on ! Find out more
ARTL icon

Artelo Biosciences
ARTL

2 hedge funds and large institutions have $25.6K invested in Artelo Biosciences in 2024 Q3 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 2 → 2 (0)

0.1% less ownership

Funds ownership: 0.8% → 0.7% (-0.1%)

28% less capital invested

Capital invested by funds: $35.7K → $25.6K (-$10K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
2
Holders Change
–
Holders Change %
0%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
-$3.09K
2
TRCT
Tower Research Capital (TRC)
New York
-$824
3
Citigroup
Citigroup
New York
-$64

ARTL Hedge Fund Activity: Q3 2024 in Review

2 of the 6,979 institutional investors tracked by Wall St. Rank reported a position in Artelo Biosciences (ARTL) for Q3 2024, worth a combined $25.6K — down 28% from $35.7K a quarter earlier.

Fund positioning in ARTL was balanced in Q3 2024: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 2 trimmed.

The largest seller was Geode Capital Management, cutting an estimated $3.09K.

  • 2 institutional investors held Artelo Biosciences (ARTL) as of Q3 2024, unchanged from Q2 2024.
  • Funds reported $25.6K of Artelo Biosciences stock for Q3 2024, down 28% quarter-over-quarter.
  • 0 funds opened new Artelo Biosciences positions in Q3 2024 and 0 closed out.
  • The largest Artelo Biosciences seller in Q3 2024 was Geode Capital Management, an estimated $3.09K sold.

Based on aggregated 13F filings for Q3 2024.